Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of RTX-321 for the Treatment of Patients With Advanced Malignancies Associated With Human Papillomavirus-16 Infection

NCT04672980 is registered in ClinicalTrials.gov with Rubius Therapeutics as lead sponsor.

NCT NCT04672980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04672980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of RTX-321 for the Treatment of Patients With Advanced Malignancies Associated With Human Papillomavirus-16 Infection
Lead sponsor
Rubius Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
April 8, 2021
Completion date
November 30, 2022
Enrollment
9 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, cervical cancer, head and neck cancer